Hye Suk Lee

Summary

Affiliation: The Catholic University of Korea
Country: Korea

Publications

  1. Choi W, Kim J, Kim D, Lee Y, Yoo J, Shin D, et al. Simultaneous Determination of Chlorogenic Acid Isomers and Metabolites in Rat Plasma Using LC-MS/MS and Its Application to A Pharmacokinetic Study Following Oral Administration of Stauntonia Hexaphylla Leaf Extract (YRA-1909) to Rats. Pharmaceutics. 2018;10: pubmed publisher
    ..Other pharmacokinetic parameters were comparable among three doses studied. AUClast values for CA, CA-3-G, and CA-4-G exceeded those for CGA, NCGA, and CCGA. ..
  2. Moon J, Kong T, Jang H, Kang H, Cho Y, Lee J, et al. Simultaneous quantification of 18 saturated and unsaturated fatty acids and 7 sterols as their tert-butyldimethylsilyl derivatives in human saliva using gas chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1092:114-121 pubmed publisher
    ..This approach can be used as a primary screening tool to examine the levels of both FAs and sterols in saliva, providing detailed information about their homeostasis for diagnostic and prognostic purposes. ..
  3. Kwon S, Kim J, Jeong H, Ahn K, Oh S, Lee H. Role of cytochrome P450 and UDP-glucuronosyltransferases in metabolic pathway of homoegonol in human liver microsomes. Drug Metab Pharmacokinet. 2015;30:305-13 pubmed publisher
    ..Glucuronidation of homoegonol to M5 was mediated by UGT1A1, UGT1A3, UGT1A4, and UGT2B7 enzymes, whereas M4 was formed from 4-O-demethylhomoegonol by UGT1A1, UGT1A8, UGT1A10, and UGT2B15 enzymes. ..
  4. Kong T, Kim J, Kim D, Lee H. Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes. Arch Pharm Res. 2018;41:691-710 pubmed publisher
  5. Kong T, Kwon S, Cheong J, Kim H, Kim J, Lee H. In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes. Molecules. 2018;23: pubmed publisher
    ..4 µM. Based on these in vitro results, we conclude that EAM-2201 has the potential to trigger in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP2C9, CYP2C19, CYP3A4 and UGT1A3. ..
  6. Wu Z, Shon J, Lee D, Park K, Park C, Lee T, et al. Lipidomic platform for structural identification of skin ceramides with α-hydroxyacyl chains. Anal Bioanal Chem. 2016;408:2069-82 pubmed publisher
    ..Based on the tandem mass spectrometry fragmentation patterns of A-type ceramides, comprehensive fragmentation schemes were proposed. Our results may be useful for identifying A-type ceramides in the stratum corneum of human skin. ..
  7. Jeong H, Kim J, Kong T, Choi W, Lee H. Comparative metabolism of honokiol in mouse, rat, dog, monkey, and human hepatocytes. Arch Pharm Res. 2016;39:516-30 pubmed publisher
    ..In conclusion, honokiol metabolism showed interspecies differences. ..
  8. Kwon S, Kim J, Jeong H, Cho Y, Oh S, Lee H. Inhibitory Effects of Aschantin on Cytochrome P450 and Uridine 5'-diphospho-glucuronosyltransferase Enzyme Activities in Human Liver Microsomes. Molecules. 2016;21: pubmed publisher
    ..These in vitro results indicate that aschantin should be examined in terms of potential interactions with pharmacokinetic drugs in vivo. It exhibited potent mechanism-based inhibition of CYP2C8, CYP2C9, CYP2C19, and CYP3A4. ..
  9. Kim J, Choi W, Moon J, Lee J, Lee S, Lee H. Metabolomics-assisted metabolite profiling of itraconazole in human liver preparations. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1083:68-74 pubmed publisher
    ..The present study expands our knowledge of ITZ metabolism and supports the suggestion that ITZ has a better safety profile than that of KCZ in terms of metabolism-mediated toxicity. ..

More Information

Publications21

  1. Jeong H, Kim J, Lee D, Shim H, Lee H. In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations. Molecules. 2015;20:21802-15 pubmed publisher
    ..These results suggest that the interindividual variability in the metabolism of evogliptin in humans is a result of the genetic polymorphism of the CYP and UGT enzymes responsible for evogliptin metabolism. ..
  2. Kim J, Kim H, Kong T, Lee J, Kim J, In M, et al. In vitro metabolism of a novel synthetic cannabinoid, EAM-2201, in human liver microsomes and human recombinant cytochrome P450s. J Pharm Biomed Anal. 2016;119:50-8 pubmed publisher
    ..In conclusion, EAM-2201 is extensively metabolized by CYPs and its metabolites can be used as an indicator of EAM-2201 abuse. ..
  3. Kong T, Kim J, Choi W, Lee J, Kim H, Kim J, et al. Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes. Anal Bioanal Chem. 2017;409:1667-1680 pubmed publisher
    ..Graphical abstract In vitro metabolic pathways of MAM-2201 were characterized in human liver microsomes and recombinant CYPs using LC-HRMS analysis. Total 19 phase I metabolites were identified with predominant contribution of CYP3A4. ..
  4. Kong T, Kim J, Kim J, In M, Choi K, Kim H, et al. Rapid analysis of drugs of abuse and their metabolites in human urine using dilute and shoot liquid chromatography-tandem mass spectrometry. Arch Pharm Res. 2017;40:180-196 pubmed publisher
    ..This method is useful for the rapid and accurate determination of multiple drug abuse with a small amount of urine in forensic and clinical toxicology. ..
  5. Kim J, Kwon S, Kong T, Cheong J, Kim H, In M, et al. AM-2201 Inhibits Multiple Cytochrome P450 and Uridine 5'-Diphospho-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes. Molecules. 2017;22: pubmed publisher
    ..These in vitro results indicate that AM-2201 needs to be examined for potential pharmacokinetic drug interactions in vivo due to its potent inhibition of CYP2C8, CYP2C9, CYP3A4, UGT1A3, and UGT2B7 enzyme activities. ..
  6. Kim J, Choi W, Lee S, Lee H. Revisiting the Metabolism and Bioactivation of Ketoconazole in Human and Mouse Using Liquid Chromatography-Mass Spectrometry-Based Metabolomics. Int J Mol Sci. 2017;18: pubmed publisher
    ..In summary, the metabolic characteristics of KCZ, including reactive metabolites, were comprehensively understood using a metabolomics approach. ..
  7. Kim J, Kwon S, Jeong H, Lee H. Inhibitory Effects of Dimethyllirioresinol, Epimagnolin A, Eudesmin, Fargesin, and Magnolin on Cytochrome P450 Enzyme Activities in Human Liver Microsomes. Int J Mol Sci. 2017;18: pubmed publisher
    ..These in vitro results suggest that it is necessary to investigate the potentials of in vivo fargesin-drug interaction with CYP2C8, CYP2C9, CYP2C19, and CYP3A4 substrates. ..
  8. Kim J, Nam W, Kim S, Kwon O, Seung E, Jo J, et al. Mechanism Investigation of Rifampicin-Induced Liver Injury Using Comparative Toxicoproteomics in Mice. Int J Mol Sci. 2017;18: pubmed publisher
    ..Taken together, this study showed in-depth molecular mechanism of rifampicin-induced liver injury by comparative toxicoproteomics approach. ..
  9. Lee C, Lee M, Yoo S, Choi K, Song J, Jang J, et al. Magnolin inhibits cell migration and invasion by targeting the ERKs/RSK2 signaling pathway. BMC Cancer. 2015;15:576 pubmed publisher
    ..These results demonstrate that magnolin inhibits cell migration and invasion by targeting the ERKs/RSK2 signaling pathway. ..
  10. Kim J, Hwang D, Moon J, Lee Y, Yoo J, Shin D, et al. Multiple UDP-Glucuronosyltransferase and Sulfotransferase Enzymes are Responsible for the Metabolism of Verproside in Human Liver Preparations. Molecules. 2017;22: pubmed publisher
    ..Based on these results, the pharmacokinetics of verproside may be affected by the co-administration of relevant UGT and SULT inhibitors or inducers. ..
  11. Kong T, Kim J, Kwon S, Cheong J, Kim H, In M, et al. Inhibition of cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes. Arch Pharm Res. 2017;40:727-735 pubmed publisher
    ..Based on these in vitro results, we conclude that MAM-2201 has the potential to trigger in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP2C9, CYP3A4, and UGT1A3. ..
  12. Song I, Kong T, Jeong H, Kim E, Kwon S, Kang H, et al. Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo. BMC Complement Altern Med. 2014;14:251 pubmed publisher
    ..Inhibitory effects of DA-9801 on OCT1, OCT2, and OAT3 observed in vitro may not necessarily translate into in vivo herb-drug interactions in rats even at its maximum effective dose. ..